Response to Four-year entecavir therapy reduces hepatocellular carcinoma, cirrhotic events and mortality in chronic hepatitis B patients
Journal
Liver International
Journal Volume
37
Journal Issue
2
Pages
310-311
Date Issued
2017
Author(s)
SDGs
Other Subjects
entecavir; antivirus agent; entecavir; guanine; virus DNA; acute hepatitis A; antiviral therapy; cancer risk; Child Pugh score; chronic hepatitis B; decompensated liver cirrhosis; drug response; hepatitis E; human; incidence; Letter; liver cell carcinoma; liver cirrhosis; mortality; public health service; risk reduction; superinfection; survival; Taiwan; analogs and derivatives; chronic hepatitis B; genetics; Hepatitis B virus; liver cell carcinoma; liver cirrhosis; liver tumor; Antiviral Agents; Carcinoma, Hepatocellular; DNA, Viral; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Humans; Liver Cirrhosis; Liver Neoplasms
Publisher
Blackwell Publishing Ltd
Type
letter